Presented By: DRI

Since the legalization of hemp, we have seen explosive growth in hemp production, specifically the production of hemp-derived CBD products (e.g., food, beverages, topicals, dietary supplements, cosmetics and much more).  However, the U.S. Food and Drug Administration (FDA), the Federal Trade Commission (FTC), states and localities, and plaintiff’s attorneys have not been shy about going after products in this space.  In this exciting and interactive session, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current CBD regulatory and litigation landscape and how they might change.

Who Should Attend: 

• Retailers/wholesalers
• Product Developers
• Distributors
• Litigators
• Regulators

What Will You Learn?: 

• How FDA, FTC, and other federal and state government agencies are regulating hemp/hemp-derived CBD products
• The FDA’s approach to CBD and understanding what action, if any, that the FDA may take near term and long term
• The importance of CBD sourcing, labeling, and testing